Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Dose Escalation Study of EMZ702 in Combination With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Non-responsive to Prior Therapy With Pegylated Interferon and Ribavirin

NCT00230854 is registered in ClinicalTrials.gov with OPKO Health, Inc. as lead sponsor.

NCT NCT00230854
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00230854 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Dose Escalation Study of EMZ702 in Combination With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Non-responsive to Prior Therapy With Pegylated Interferon and Ribavirin
Lead sponsor
OPKO Health, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2005
Completion date
July 31, 2007
Enrollment
28
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c, hepatitis, viral, human